Aarti Pharmalabs AARTIPHARM
Pharma intermediates, xanthine derivatives (caffeine) and APIs, with a CDMO business
Mapped in 1 theme: Pharmaceuticals.
Where Aarti Pharmalabs sits in the supply chain
Aarti Pharmalabs appears in 1 supply-chain layer in one theme, Pharmaceuticals.
Pharmaceuticals › KSMs & intermediates
Direct supplierOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 1,853 | 2,115 | 1,819 |
| Net profit | 217 | 272 | 175 |
Latest-year revenue ₹1,819 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- Intermediates-to-API chemistry depth inherited from Aarti Industries
- CDMO adds higher-margin contract work
Risks
- FY26 revenue fell 14% and profit 36%
- Xanthine pricing pressure from China
Common questions
What does Aarti Pharmalabs do?
Pharma intermediates, xanthine derivatives (caffeine) and APIs, with a CDMO business.
Where does Aarti Pharmalabs sit in the supply chain?
Aarti Pharmalabs (NSE: AARTIPHARM) is mapped in 1 supply-chain layer: KSMs & intermediates (Pharmaceuticals).
Who are Aarti Pharmalabs' peers?
In the KSMs & intermediates layer of Pharmaceuticals: IOL Chemicals & Pharmaceuticals, Vinati Organics, Aarti Drugs, Granules India and Aurobindo Pharma.
What is Aarti Pharmalabs' market cap and valuation?
As of 30 Oct 2026: market cap ₹7,914 Cr, P/E 30.4x, ROCE 10.7%, ROE 8.6%, dividend yield 0.40%.